Cerebrovascular Disorders
A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
Subtype terms (18)
More specific conditions that are subtypes of Cerebrovascular Disorders in the MeSH hierarchy.
- Basal Ganglia Cerebrovascular Disease
- Brain Ischemia
63 drugs (45 approved, 18 experimental)
- Carotid Artery Diseases
49 drugs (34 approved, 15 experimental)
- Cerebral Small Vessel Diseases
26 drugs (21 approved, 5 experimental)
- Cerebrovascular Trauma
7 drugs (5 approved, 2 experimental)
- Dementia, Vascular
51 drugs (32 approved, 19 experimental)
- Intracranial Arterial Diseases
9 drugs (5 approved, 4 experimental)
- Intracranial Arteriovenous Malformations
1 drug approved
- Intracranial Embolism and Thrombosis
1 drug approved
- Intracranial Hemorrhages
52 drugs (44 approved, 8 experimental)
- Leukomalacia, Periventricular
14 drugs (11 approved, 3 experimental)
- Sneddon Syndrome
1 drug approved
- Stroke
409 drugs (237 approved, 172 experimental)
- Susac Syndrome
- Vascular Depression
4 drugs approved
- Vascular Headaches
3 drugs approved
- Vasculitis, Central Nervous System
10 drugs (6 approved, 4 experimental)
- Vasospasm, Intracranial
25 drugs (23 approved, 2 experimental)
Drugs by status
Approved for this indication (7)
Phase 4 trials (16)
Phase 3 trials (19)
Phase 2 trials (15)
Phase 1 trials (2)
Other trials (24)
Organizations
Organization Involved with Phase 4 Indications (13)
Organization Involved with Phase 3 Indications (24)
- Kobe University
- Foundation for Biomedical Research and Innovation
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute on Aging (NIA)
- Huazhong University of Science and Technology
- Harvard University
- Kyushu University
- NHS Lothian
- Sichuan University
- Tohoku University
- Tokyo Women's Medical University
- Translational Research Informatics Center, Kobe, Hyogo, Japan
- University of Edinburgh
- University of Southern California
- University of Toronto
- University of Bergen
- Chinese University of Hong Kong
- Health Solutions, India
- SMT KASHIBAI NAVALE MEDICAL COLLEGE
- Saiseikai Central Hospital
- University of New South Wales
- Chinese Academy of Medical Sciences
- The University of Texas, Dallas
Organization Involved with Phase 2 Indications (23)
- Regenera Pharma Ltd
- Schwabe
- D-Pharm Ltd.
- National Neuroscience Institute
- Shahid Beheshti University of Medical Sciences
- Emory University
- Memorial University of Newfoundland
- Nanjing University
- University of Science Malaysia
- Wake Forest University
- University of Waterloo
- Dalhousie University
- University of British Columbia
- University of Calgary
- Isfahan University
- University of Oxford
- ActivBiotics Pharma
- Toronto Memory Program
- Wellcome Trust
- Brain Canada
- Applied Health Research Centre
- Government of Malaysia
- Jinlin University
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (5)